Bevacizumab (Avastin) Into the Tumor Resection Cavity in Subjects With Glioblastoma Multiforme at First Recurrence
This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.
Glioblastoma Multiforme
DRUG: Avastin
Maximum Tolerated Dose of bevacizumab (Avastin) following local administration., 4 weeks
Number of Adverse Events, All adverse events will be recorded in the case report form., 12 months|Progression Free Survival, Patients will be followed for survival as well as disease progression for 12 months after treatment., 12 months
This is a phase 1b study for safety and tolerability of bevacizumab(Avastin)administered into the tumor resection cavity in subjects with Glioblastoma Multiforme (GBM) at first recurrence.